Advertisement Fidelity
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

MSTX RSS Feed
Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Ecomike, LaJollaCA, Rhodey Red
Search This Board:
Last Post: 4/20/2014 7:17:03 AM - Followers: 295 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.


http://wsw.com/webcast/cowen16/MSTX/  Webcast from Cowen Healthcare Conference 03/03/14

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_07.09.2013.pdf


http://www.media-server.com/m/p/to9vgb8uhttp://www.media-server.com/m/p/to9vgb8u  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_10.08.2013.pdf    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW

http://www.masttherapeutics.com/company/ceo-blog/ 
Blog Update from CEO B. Culley 12/12/13  NEW

http://www.masttherapeutics.com/investors/news/?releaseid=1887966  Data From Proof of Concept Study in Heart Failure 
01/06/13


ClinicalTrials.gov

 
A service of the U.S. National Institutes of Health

 

Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Sponsor:
Information provided by (Responsible Party):
Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01737814
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.


Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

Resource links provided by NLM:


Further study details as provided by Mast Therapeutics, Inc.:

Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]

  • Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]

Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline

 

 
Please refer to this study by its ClinicalTrials.gov identifier: NCT01737814

Contacts
Contact: Mast Therapeutics CT.gov Call Center 1-888-965-1238  

 
Responsible Party: Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 25, 2013

 

Technology

 

Hematology

MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.


Oncology

Exelbine™

Exelbine™, or ANX-530 (vinorelbine injectable emulsion), is a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®). We are seeking a partner or outside investor to continue development of the Exelbine program.

ANX-514

ANX-514 (docetaxel for injectable emulsion) is a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel. We are seeking a partner or outside investor to continue development of the ANX-514 program.



2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing


Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule


Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14

Initiate Nonclinical POC Study in Stroke Q2 '14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14


 

Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug 
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be 
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.pdf

http://whalewisdom.com/stock/mstx

http://whalewisdom.com/schedule13d/view/90323

http://whalewisdom.com/schedule13d/view/103504

http://whalewisdom.com/schedule13d/view/90288

http://whalewisdom.com/filer/stock_history/ancora-advisors-llc/mstx/
 

Schedule 13D and 13G filings submitted since 03/31/2013

  Filing Company Date of
Filing
Total Reported
Shares Owned
Shares Reported
on 13F
SC 13G GREAT POINT PARTNERS LLC 09/30/2013 8,700,000 5,442,400
SC 13G SABBY MANAGEMENT, LLC 01/14/2014 4,105,500 3,639,571
SC 13G FRANKLIN RESOURCES INC 07/10/2013 10,987,000 12,046,100
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F 2013-03-31 MAST THERAPEUTICS INC MSTX 875,000 New 0.11
13F 2013-06-30 MAST THERAPEUTICS INC MSTX 1,848,045 973,045 0.14
 




                                                                         






http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381

http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928

http://stockcharts.com/freecharts/gallery.html?MSTX

                                                         

Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries
info@mastthera.com

Investor Relations Contact
ir@mastthera.com

Business Development Contact
busdev@mastthera.com

Careers Contact
hr@mastthera.com

 

                                                                                                 

                                                                                                                                                     

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MSTX
Current Price
Volume:
Bid Ask Day's Range
Wiki
ANX News: Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease 04/14/2014 08:00:00 AM
ANX News: Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc. 02/10/2014 08:00:00 AM
PostSubject
#11960   Very interesting. This can only increase the senderos 04/20/14 07:17:03 AM
#11959   Thanks for the link, that looks very good The Silver Man 04/20/14 01:37:48 AM
#11958   http://www.vistapglobal.com/2014/04/vista-partners-commentary-interview-mast-the LaJollaCA 04/19/14 04:14:04 PM
#11957   Thanks Joe!!! Rhodey Red 04/17/14 10:25:43 PM
#11956   Wonder why they never put info about it pray 04/17/14 08:43:14 AM
#11955   If you look under the Crisis Voice heading Joe08 04/17/14 08:13:31 AM
#11954   ON HISTORIC GRAF sedrik 04/16/14 10:04:13 AM
#11953   Interesting, never seen or heard about this. How pray 04/16/14 09:34:36 AM
#11952   down to 0.45 like 2013 same scenario sedrik 04/16/14 09:26:46 AM
#11951   Joe very cool find of an interesting new Rhodey Red 04/16/14 08:34:51 AM
#11950   Mast created an SCD app Joe08 04/15/14 04:25:50 PM
#11949   IMO it will elevate. I do not feel pray 04/14/14 02:05:18 PM
#11948   Well said!! LaJollaCA 04/14/14 01:49:47 PM
#11947   The truth is that you have no idea Gravitate_Z 04/14/14 01:35:28 PM
#11946   Here comes the mid day reversal plan_of_action 04/14/14 12:54:55 PM
#11945   Looks like a new bottom plan_of_action 04/14/14 12:27:48 PM
#11944   You won't be saying that by midweek when The Silver Man 04/14/14 12:09:52 PM
#11943   Great update and needed PR glad I loaded pray 04/14/14 09:54:12 AM
#11942   Mast Therapeutics Reports Data Supporting MST-188 In Sickle senderos 04/14/14 08:49:09 AM
#11941   Data Release Premarket Today. http://www.cnbc.com/id/101580445 Rhodey Red 04/14/14 08:10:50 AM
#11940   it is item 1 nsomniyak 04/12/14 11:14:53 AM
#11939   CORRECTION ON MARKETS PUSH DOWN TO 0.45 sedrik 04/12/14 04:19:22 AM
#11938   This is only my guess, but when I AKAPAK 04/11/14 08:02:37 PM
#11937   What I do not understand is right before pray 04/11/14 04:49:33 PM
#11936   a bottom here,thats what I'm hoping 123tom 04/11/14 04:00:32 PM
#11935   MSTX:Oversold. RSI (14) 27.82 Is good! lecorb 04/11/14 03:56:46 PM
#11934   Moderator pleaae delete the personal attack against Pray. 123tom 04/11/14 03:32:11 PM
#11933   Just ignore him/her. LaJollaCA 04/11/14 02:25:11 PM
#11932   You are correct on boring, everything else you pray 04/11/14 01:56:42 PM
#11930   IMO Management failure. Yes bio fiend down, but pray 04/11/14 12:57:21 PM
#11929   Anyone owning ANY bios are down with the AKAPAK 04/11/14 12:38:41 PM
#11928   Wow, this is getting ugly. pray 04/11/14 11:49:05 AM
#11927   Pray, all is well. Can't change history, only Rhodey Red 04/10/14 08:12:19 AM
#11926   You are correct, I am sure I have pray 04/09/14 09:23:46 PM
#11925   Pray, post#10952 on 12/05 was my original reply Rhodey Red 04/09/14 03:05:36 PM
#11924   No, I would have remembered ... pray 04/09/14 11:56:03 AM
#11923   Pray,quite certain I did address my positions previously, Rhodey Red 04/09/14 08:11:18 AM
#11922   There are many good biotechs out there where 123tom 04/09/14 04:11:44 AM
#11921   Questions concerning positions never addressed. My point was pray 04/08/14 11:54:29 PM
#11920   Pray, we've already had this discussion my friend. Rhodey Red 04/08/14 09:59:24 PM
#11919   TSM, some nights I have the energy to Rhodey Red 04/08/14 09:52:52 PM
#11918   I have been adding. IMO going to drop pray 04/08/14 05:34:27 PM
#11917   May not have fallen, may just work for pray 04/08/14 05:20:08 PM
#11916   I think we will see the 57 cent 123tom 04/08/14 02:36:20 PM
#11915   Rhod - You have fell for this sucker The Silver Man 04/08/14 10:41:43 AM
#11914   Sad how company treats shareholders. At the close pray 04/07/14 11:35:59 PM
#11913   yes, I hear you saying this....got it. 123tom 04/07/14 06:07:56 PM
#11912   What do you mean "are"? pray 04/07/14 06:01:30 PM
#11911   Trigger, do you still like the outlook for 123tom 04/07/14 05:48:37 PM
#11910   You picked a good stock to see some pray 04/07/14 01:59:33 PM
PostSubject